TA
SPRY icon

TFG Advisers’s ARS Pharmaceuticals SPRY Stock Holding History

TFG Advisers’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,291
Closed -$155K – 211
2025
Q1 		$155K Sell
12,291
-148
-1% -$1.78K 0.06% 207
2024
Q4 		$131K Buy
12,439
+40
+0.3% +$560 0.05% 207
2024
Q3 		$180K Buy
+12,399
New +$147K 0.06% 206

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TFG Advisers's SPRY Position: Q2 2025 in Review

TFG Advisers sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 12,291 shares — an estimated $155K sold.

TFG Advisers first reported a position in SPRY in Q3 2024 and held it in 3 quarters. The position peaked at $180K in Q3 2024. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

  • TFG Advisers reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • TFG Advisers sold 12,291 ARS Pharmaceuticals shares in Q2 2025, an estimated $155K.
  • TFG Advisers first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • TFG Advisers's ARS Pharmaceuticals position peaked at $180K in Q3 2024.
  • 187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on TFG Advisers's 13F filing for Q2 2025, filed 21 Jul 2025.